Current Report Filing (8-k)
March 11 2021 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported):
March 9, 2021
RenovaCare, Inc.
(Exact Name of Registrant as Specified in Charter)
Nevada
|
000-30156
|
98-0384030
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
4 Becker Farm Road, Suite 105 Roseland, NJ 07068
|
(Address of Principal Executive Offices) (Zip Code)
|
(888) 398-0202
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act: None
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 7 - Regulation FD
Item 7.01. Regulation FD Disclosure
Management of RenovaCare, Inc. (the "Company")
issued a pre-recorded presentation at the 2021 H.C. Wainwright Global Life Sciences Conference,
which took place on March 9th through March 10th of 2021 (The “RenovaCare Global Life Sciences Presentation”).
The RenovaCare Global Life Sciences Presentation, among other matters, provided an overview of the Company’s patented
CellMist™ and SkinGun™ technologies, business performance and strategy and its 2021 business objectives, and
was available for viewing by all participants attending the conference. A copy of the slide presentation included in the RenovaCare
Global Life Sciences Presentation is attached hereto as 99.1 in Item 9.01.
By furnishing this Current Report on Form 8-K (the “Current
Report”) and furnishing the information contained herein, the Company makes no admission as to the materiality of any
information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the RenovaCare
Global Life Sciences Presentation is summary information that is intended to be considered in the context of the Company's
Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make,
by press release or otherwise, from time to time (collectively, the “Presentation Materials”). The
Company undertakes no duty or obligation to publicly update or revise the Presentation Materials, although it may do so from time
to time as its management believes is warranted. Any such updating may be made through the filing of other reports or
documents with the SEC, through press releases or through other public disclosure.
Subsequent to the closing of the conference, the slide presentation
will be available for viewing on the Company’s website.
The information presented in Item 7.01 of this
Current Report and Exhibits 99.1 to this Current Report shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed”
under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended,
or the Exchange Act.
Section 9 - Financial Statements and
Exhibits
Item 9.01 Financial Statements and Exhibits
Number
|
|
Description
|
99.1
|
|
Presentation Materials utilized at the RenovaCare Global Life Sciences Presentation.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on March
9, 2021.
RenovaCare, Inc.
By: /s/ Alan L. Rubino
Alan L. Rubino
Chairman, President and Chief Executive Officer
RenovaCare (CE) (USOTC:RCAR)
Historical Stock Chart
From Apr 2024 to May 2024
RenovaCare (CE) (USOTC:RCAR)
Historical Stock Chart
From May 2023 to May 2024